ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.495,21
-0,34%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Kanada
  5. TSX
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) News

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:TSX:EPRX
DatumZeitQuelleÜberschriftSymbolFirma
23/05/202423h00PR Newswire (US)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
23/05/202423h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
22/05/202413h00PR Newswire (US)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
22/05/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
21/05/202423h00PR Newswire (US)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
21/05/202423h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
14/05/202413h00PR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
14/05/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
08/05/202423h03PR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
08/05/202423h03PR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
02/05/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
02/05/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
11/04/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
11/04/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
08/04/202413h00PR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
08/04/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
05/04/202413h00PR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
05/04/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
03/04/202423h00PR Newswire (Canada)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
03/04/202423h00PR Newswire (US)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
01/04/202423h01PR Newswire (US)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
01/04/202423h01PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
12/03/202414h41PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
12/03/202414h39PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
11/03/202421h06PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
11/03/202421h04PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/202423h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
01/02/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
30/01/202413h00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeTSX:EPRXEupraxia Pharmaceuticals Inc
09/01/202400h44PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX

Kürzlich von Ihnen besucht

TG
DTE
Deutsche Telekom
TG
MBG
MercedesBenz
AMEX
XLF
Financial Select Sector
DBI
TDXP
Tec DAX
PM
XAUUSD
Gold vs US Dollar
TG
LHA
Deutsche Lufthansa
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
ETHUSD
Ethereum
NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
NASDAQ
GOOGL
Alphabet
CCOM
US100
US Tech 100
TG
DBK
Deutsche Bank
NYSE
XOM
Exxon Mobil
FX
EURGBP
Euro vs Sterling
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten